Shares of ResMed Inc. RMD shed 2.00% to $220.25 Tuesday, on what proved to be an all-around dismal trading session for the ...

Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The company has a ...

Resmed (RMD) announced the publication of a meta-analysis in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly ...

CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea, according to a landmark meta-analysis supported by Resmed and published in The Lancet Respiratory Medicine ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

ResMed showed 29% EPS growth last quarter. Sales gains came in at 10%. ResMed earns the No. 6 rank among its peers in the ...

Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of dy ...

ResMed has launched a rebrand to unify its portfolio and reflect its increasing direct-to-consumer engagement.

Despite good sleep being essential for our overall health, productivity, and relationships, millions worldwide struggle with ...

Resmed (NYSE: RMD) announced today that it began a comprehensive brand evolution to unify its brand portfolio.

Resmed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered ...